Search

Your search for "adtx" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer

March 8, 2023

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Retains Top Banking Firm to Support Growth, Revenue-Generating Strategy

March 3, 2023

Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG will be supporting Aditxt’s strategic growth and revenue generating plans for its subsidiary Pearsanta Inc., […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

February 14, 2023

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

January 20, 2023

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

January 11, 2023

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the […]

News Articles

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

January 10, 2023

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also announced the appointment of Dr. Joachim-Friedrich Kapp, M.D., Ph.D., as the CEO of Adimune(TM) and […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies

January 3, 2023

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA […]

News Articles

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

December 28, 2022

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies are being developed to retrain the immune system to induce tolerance, to address, among other […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

November 28, 2022

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program

October 21, 2022

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model

October 12, 2022

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation

October 7, 2022

Aditxt (NASDAQ: ADTX), a biotech innovation company, has announced that its AditxtScore(TM) is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19. In the clip, the Aditxt team provides a virtual tour of […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

September 29, 2022

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering

September 27, 2022

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company today provided shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering. “Aditxt’s key to success is multifaceted and tied […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering

September 21, 2022

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering

September 16, 2022

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses

August 12, 2022

Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this […]

News Articles

Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses

August 2, 2022

Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system  Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Bell2Bell Podcast

Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

July 14, 2022

Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study

July 8, 2022

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Helping Individuals Make More Informed Decisions

July 1, 2022

Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Pursuing Strategy Against COVID-19, Immune System-Related Maladies

June 28, 2022

Aditxt (NASDAQ: ADTX) is focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions. “Aditxt is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection,” […]

News Articles

Aditxt Inc. (NASDAQ: ADTX) Authorizes New Channel Partner to Offer AditxtScore(TM) Amid Rising COVID-19 Cases and Possible Fall/Winter Waves

Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial product Aditxt recently announced it had […]

News Articles

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

June 24, 2022

Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd No additional funding for COVID-19 relief has been approved by […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Added to PMLS Menu of Testing Services

June 14, 2022

Premier Medical Laboratory Services (“PMLS”), a nation-leading advanced medical diagnostics lab, today announced that it has added Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) to its menu of testing services. AditxtScore provides more clarity regarding a patient’s individual immunity profile and allows patients to know their level of protection that an immune response to the virus or vaccination […]

News Articles

Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the […]

News Articles

New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

June 10, 2022

Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Engages IBN for Corporate Communications Expertise

June 9, 2022

Aditxt (NASDAQ: ADTX), a biotech innovation company, today announced that it has selected the corporate communications expertise of IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Technology at the Right Time’

June 6, 2022

Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability […]

InvestorNewsBreaks

InvestorNewsBreaks – Why Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

May 27, 2022

Aditxt (NASDAQ: ADTX) is a biotech company commercializing new innovations. The company’s first commercial product, AditxtScore(TM), is an immune mapping technology designed to provide a personalized, comprehensive profile of an individual’s immune system. “The company’s first commercial application of the platform, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 […]

News Articles

Aditxt Inc. (NASDAQ: ADTX) Planning Nationwide Rollout of its AditxtScore(TM) Immune Monitoring Platform

May 23, 2022

Aditxt recently entered a multi-year partnership with GRS for the promotion of its proprietary AditxtScore Immune Monitoring Platform Aditxt plans to roll out the monitoring platform to medical offices, pharmacies, laboratories, and employers across the country, with promotion through nationwide television commercials  AditxtScore(TM) monitors the current immune response not genetic sequencing  Continuing research into COVID-19 […]

News Articles

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

May 16, 2022

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune system Aditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globally The company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indications Aditxt intends […]

Press Releases

IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc.

August 2, 2022

LOS ANGELES, Aug. 02, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates […]

Press Releases

Aditxt Engages IBN (InvestorBrandNetwork) To Bolster Its Corporate Communications Efforts

June 9, 2022

LOS ANGELES, June 09, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a biotech innovation company, today announces it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities. Aditxt is developing and commercializing new innovations aimed at monitoring and reprogramming the […]

Press Releases

Bad Crypto Podcast and RAILGUN Form Partnership

November 3, 2021

NEW YORK, Nov. 03, 2021 (GLOBE NEWSWIRE) — via InvestorWire — RAILGUN, a revolutionary smart contracts protocol and DeFi game-changer, is thrilled to announce an agreement with the prominent Bad Media Group to raise its market visibility and adoption goals. The Bad Media Group, led by crypto-blockchain influencers and hosts of the popular Bad Crypto Podcast (BCP) and The Nifty Show live […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).